PCI Biotech Holding ASA (FRA:4QG) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PCI Biotech Holding ASA's Free Cash Flow for the three months ended in Dec. 2024 was €0.00 Mil. PCI Biotech Holding ASA's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, PCI Biotech Holding ASA's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, PCI Biotech Holding ASA's current FCF Yield % is -26.88%.

The historical rank and industry rank for PCI Biotech Holding ASA's FCF Margin % or its related term are showing as below:

FRA:4QG's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.22
* Ranked among companies with meaningful FCF Margin % only.

PCI Biotech Holding ASA FCF Margin % Historical Data

The historical data trend for PCI Biotech Holding ASA's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA FCF Margin % Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

PCI Biotech Holding ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of PCI Biotech Holding ASA's FCF Margin %

For the Biotechnology subindustry, PCI Biotech Holding ASA's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's FCF Margin % distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's FCF Margin % falls into.

PCI Biotech Holding ASA FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

PCI Biotech Holding ASA's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-1.171	/	0
	=	%

PCI Biotech Holding ASA's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0	/	0
	=	%

PCI Biotech Holding ASA FCF Margin % Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PCIB:Norway 0JGL:UK

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines